Pau d'arco (Lapacho) Extract *HEF

Quantità: 60ml
Prezzo: 26.90€

Aggiungi al carrello

Opinioni dei Clienti (0)

La corteccia di pau d'arco è impiegata dalla medicina popolare dell'Amazzonia come rimedio per psoriasi e dermatiti, oltre che Candida, infezioni da lieviti o funghi (sia internamente che topicamente), malattie trasmissibili sessualmente.

Che cosa significa "HEF"? Per scoprirlo, clicca qui.

Perchè acquistare questo Pau d'arco? Per saperne di più clicca qui.

Ingredienti: 100% pura corteccia di pau d'arco (Tabebuia impetiginosa), estratta impiegando un metodo di estrazione che procura l'equivalente di circa 500 mg di corteccia per millilitro di estratto.

Uso suggerito: Come supplemento nutrizionale, assumere 60 gocce 2 o più volte al giorno o secondo le indicazioni di uno specialista.

Controindicazioni: Non usare in gravidanza o durante l'allattamento.

Interazioni con farmaci: Nessuna segnalata.

Altre indicazioni pratiche: Singoli dosaggi molto elevati di decotti di pau d'arco possono causare malessere intestinale e/o nausea. Non assumere dosaggi elevati se non su consiglio di uno specialista. Ridurre il dosaggio in caso di nausea.

Chi ha acquistato Pau d'arco Extract ha richiesto anche:

A-F, miscela di erbe dell'Amazzonia usate come rimedi popolari per le infezioni da funghi e lieviti
Jatobà Extract, erba della foresta pluviale utilizzata dagli indigeni contro cistiti e Candida
Graviola Max, miscela di Annona muricata e Annona montana
Skin-P Support, formulazione al 100% naturale di piante dell'Amazzonia impiegate dagli sciamani per disturbi della pelle come psoriasi, eczema, dermatite, rosacea e come supporto per pelli sensibili e danneggiate

Bibliografia su Pau d'arco

Sulle azioni antimicrobiche (funghi, lieviti, batteri, virus):
Pereira, E. M., et al. "Tabebuia avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis." Ann. Clin. Microbiol. Antimicrob. 2006 Mar; 5: 5.
Park, B. S., et al. "Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori." J. Ethnopharmacol. 2006 Apr; 105(1-2): 255-62.
Park, B. S., et al. “Selective growth-inhibiting effects of compounds identified in Tabebuia impetiginosa inner bark on human intestinal bacteria.” J. Agric. Food Chem. 2005 Feb; 23;53(4): 1152-7.
Park, B. S., et al. “Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori.” J. Ethnopharmacol. 2005 Dec;
Machado, T. B., et al. “In vitro activity of Brazilian medicinal plants, naturally occurring naphthoquinones and their analogues, against methicillin-resistant Staphylococcus aureus.” Int. J. Antimicrob. Agents. 2003; 21(3): 279-84.
Portillo, A., et al. “Antifungal activity of Paraguayan plants used in traditional medicine.” J. Ethnopharmacol. 2001; 76(1): 93–8.
Nagata, K., et al. “Antimicrobial activity of novel furanonaphthoquinone analogs.” Antimicrobial Agents Chemother. 1998; 42(3): 700–2.
Binutu, O. A., et al. “Antimicrobial potentials of some plant species of the Bignoniaceae family.” Afr. J. Med. Sci. 1994; 23(3): 269–73.
Giuraud, P., et al. “Comparison of antibacterial and antifungal activities of lapachol and b-lapachone.” Planta Med. 1994; 60: 373–74.
Li, C. J., et al. “Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.” Proc. Nat’l. Acad. Sci. USA 1993; 90(5): 1839–42.
Anesini, C., et al. “Screening of plants used in Argentine folk medicine for antimicrobial activity.” J. Ethnopharmacol. 1993; 39(2): 119–28.
Lagrota, M., et al. “Antiviral activity of lapachol.” Rev. Microbiol. 1983; 14: 21–6.
Gershon, H., et al. “Fungitoxicity of 1,4-naphthoquinonoes to Candida albicans and Trichophyton menta grophytes.” Can. J. Microbiol. 1975; 21: 1317–21.
Linhares, M. S., et al. “Estudo sobre of efeito de substancias antibioticas obitdas de Streptomyces e vegatais superiores sobre o herpesvirus hominis.” Revista Instituto Antibioticos, Recife 1975; 15: 25–32.

Sulle azioni anticancro e anti-leucemia:
Larsson, D. E., et al. "Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines." Anticancer Res. 2006 Nov-Dec; 26(6B): 4125-9.
Bey, E. A., et al. "Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses." J. Cell Physiol. 2006 Dec; 209(3): 604-10.
Kung, H. N., et al. "Involvement of NO/cGMP signaling in the apoptotic and anti-angiogenic effects of beta-lapachone on endothelial cells in vitro." J. Cell Physiol. 2006 Dec 27;
Bentle, M. S., et al. "Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair." J. Biol. Chem. 2006 Nov; 281(44): 33684-96.
Sun, X., et al. "Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway." Cell Cycle. 2006 Sep; 5(17): 2029-35.
Woo, H. J., et al. "Beta-lapachone, a quinone isolated from Tabebuia avellanedae, induces apoptosis in HepG2 hepatoma cell line through induction of Bax and activation of caspase." J. Med. Food. 2006 Summer; 9(2):161-8.
Suzuki, M., et al. "Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro." Radiat. Res. 2006; 165(5): 525-31.
Lee, J. I., et al. "Beta-lapachone induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2 family and activation of caspases." Exp. Oncol. 2006 Mar; 28(1): 30-5.
Lee, J. H., et al. “Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells.” Pharmacol. Res. 2005; 51(6): 553-60.
Reinicke, K. E., et al. “Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.” Clin. Cancer Res. 2005 Apr; 11(8): 3055-64.
Woo, H. J., et al. “Growth inhibition of A549 human lung carcinoma cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity.” Int. J. Oncol. 2005; 26(4): 1017-23.
Park, H. J., et al. “Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.” Clin. Cancer Res. 2005 Dec; 11(24 Pt 1): 8866-71.
Balassiano, I. T., et al. “Demonstration of the lapachol as a potential drug for reducing cancer metastasis. Oncol. Rep. 2005; 13(2): 329-33.
Ough, M., et al. "Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1." Cancer Biol. Ther. 2005 Jan; 4(1): 95-102.
Park, H. J., et al. "Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation." Int. J. Radiat. Oncol. Biol. Phys. 2005 Jan; 61(1): 212-9.
Kumi-Diaka, J., et al. "Potential mechanism of phytochemical-induced apoptosis in human prostate adenocarcinoma cells: Therapeutic synergy in genistein and beta-lapachone combination treatment." Cancer Cell Int. 2004 Aug; 4(1): 5.
Choi, B. T., et al. “beta-Lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-kappaB in human colon cancer HCT-116 cells.” Anticancer Drugs. 2003 Nov; 14(10): 845-50.
Renou, S. G., et al. “Monoarylhydrazones of alpha-lapachone: synthesis, chemical properties and antineoplastic activity.” Pharmazie. 2003 Oct; 58(10): 690-5.
Choi, Y. H., et al. “Suppression of human prostate cancer cell growth by beta-Lapachone via down-regulation of PRB phosphorylation and induction of Cdk Inhibitor p21(WAF1/CIP1).” J. Biochem. Mol. Biol. 2003 Mar; 36(2): 223-9.
Colman de Saizarbitoria, T., et al. “Bioactive furonaphtoquinones from Tabebuia barbata (Bignoniaceae).” Acta Cient. Venez. 1997; 48(1): 42-6.
Ueda, S., et al. “Production of anti-tumour-promoting furanonaphthoquinones in Tabebuia avellanedae cell cultures.” Phytochemistry. 1994 May; 36(2): 323-5.
Schuerch, A. R., et al. “B-Lapachone, an inhibitor of oncornavirus reverse transcriptase and eukarotic DBA Polymerase-A. Inhibitory effect, thiol dependency and specificity.” Eur. J. Biochem. 1978; 84: 197–205.
Linardi, M. D. C., et al. “A lapachol derivative active against mouse lymphocyte leukemia P-388.” J. Med. Chem. 1975; 18(11): 1159–62.
Block, J. B., et al. “Early clinical studies with lapachol (NSC-11905).” Cancer Chemother. Rep. 1974; 4: 27–8.
Santana, C. F., et al. “Preliminary observation with the use of lapachol in human patients bearing malignant neoplasms.” Revista do Instituto de Antibioticos 1971; 20: 61–8.
Rao, K. V., et al. “Recognition and evaluation of lapachol as an antitumor agent.” Canc. Res. 1968; 28: 1952–54.

Sulle azioni antinfiammatorie e anti-dolorifiche:
Awale, S., et al. ”Nitric oxide (NO) production inhibitory constituents of Tabebuia avellanedae from Brazil.” Chem. Pharm. Bull. 2005; 53(6): 710-3.
Lee, J. H., et al. "Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells." Pharmacol. Res. 2005; 51(6): 553-60.
de Miranda, F. G., et al. “Antinociceptive and antiedematogenic properties and acute toxicity of Tabebuia avellanedae Lor. ex Griseb. inner bark aqueous extract.” BMC. Pharmacol. 2001; 1(1): 6.
Oga, S., et al. “Toxicidade e atividade anti-inflamatoria de Tabebuia avellanedae Lorentz (‘Ipe Roxo’).” Rev. Fac. Farm. Bioquim. 1969; 7: 4.

Sulle azioni anti-psoriasi:
Muller, K., et al. “Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.” J. Nat. Prod. 1999; 62(8): 1134–36.

Sulle azioni antiossidanti:
Park, B. S., et al. “Antioxidant activity and characterization of volatile constituents of Taheebo (Tabebuia impetiginosa Martius ex DC).” J. Agric. Food Chem. 2003; 51(1): 295-300.

Sulle azioni antivenine:
Nunez, V., et al. “Neutralization of the edema-forming, defibrinating and coagulant effects of Bothrops asper venom by extracts of plants used by healers in Colombia.” Braz. J. Med. Biol. Res. 2004; 37(7): 969-77.
Otero, R., et al. “Snakebites and ethnobotany in the northwest region of Colombia. Part III: neutralization of the haemorrhagic effect of Bothrops atrox venom.” J. Ethnopharmacol. 2000 Nov; 73(1-2): 233-41.
Otero, R., et al. “Snakebites and ethnobotany in the northwest region of Colombia: Part II: neutralization of lethal and enzymatic effects of Bothrops atrox venom.” J. Ethnopharmacol. 2000 Aug; 71(3): 505-11.

Sulle azioni antiparassitarie e antimalariche:
Ferreira, V. F., et al. "Trypanocidal agents with low cytotoxicity to mammalian cell line: a comparison of the theoretical and biological features of lapachone derivatives." Bioorg. Med. Chem. 2006 Aug; 14(16): 5459-66.
Silva, R. S., et al. "Synthesis of naphthofuranquinones with activity against Trypanosoma cruzi." Eur. J. Med. Chem. 2006 Apr; 41(4): 526-30.
Menna-Barreto, R. F., et al. "Effect of a beta-lapachone-derived naphthoimidazole on Trypanosoma cruzi: identification of target organelles." J. Antimicrob. Chemother. 2005 Dec; 56(6): 1034-41.
Perez-Sacau, E., et al. "Antiplasmodial activity of naphthoquinones related to lapachol and beta-lapachone." Chem. Biodivers. 2005; 2(2): 264-74.
Lima, N. M., et al. "Antileishmanial activity of lapachol analogues." Mem. Inst. Oswaldo Cruz. 2004 Nov; 99(7): 757-61.
de Andrade-Neto, V. F., et al. "Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo." Bioorg. Med. Chem. Lett. 2004 Mar; 14(5): 1145-9.
Pinto, C. N., et al. “Chemical reactivity studies with naphthoquinones from Tabebuia with anti-trypanosomal efficacy.” Arzneimittelforschung. 2000; 50(12): 1120-8.
Austin, F. R. “Schistosoma mansoni chemoprophylaxis with dietary lapachol.” Am. J. Trop. Med. Hyg. 1979; 23: 412–19.
Gilbert, B., et al. “Schistosomiasis. Protection against infection by terpenoids.” An. Acad. Brasil. Cienc. 1970; 2 (Suppl): 397–400.

AVVERTENZA: Le informazioni fornite in queste pagine hanno solo scopo informativo e sono tratte da pubblicazioni internazionali. Le proprietà naturali delle erbe sono unicamente da riferire alle comuni utilizzazioni nella tradizione popolare ed erboristica. I nostri prodotti non si propongono di diagnosticare, trattare, curare o prevenire alcuna malattia. Non si intende fornire suggerimenti per diagnosi o trattamenti di malattie. In caso di necessità consultare un medico.